A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Mechanism of action

Evidence map: Citicoline

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

CDP-choline is the intermediate from which cells build phosphatidylcholine; as a drug, it is called citicoline [1]. In humans, it is cleaved after oral intake: in a randomized crossover study of twelve people, choline and uridine rose in the blood, and cytidine was hardly detectable. The research team concludes that in humans, uridine and choline supply the building blocks for membrane synthesis in the brain, not cytidine as in rats [2].

In ischemia models in rodents, citicoline protected membrane lipids such as phosphatidylcholine, sphingomyelin, and cardiolipin, increased glutathione synthesis, and reduced lipid peroxidation; a review explains this mainly by inhibition of phospholipase A2. In addition, citicoline supplies choline for acetylcholine and, according to the same review, increases the activity of tyrosine hydroxylase and dopamine release [3]. In humans, after six weeks, phosphodiesters in the brain of healthy older people rose by 7.3%, albeit without a placebo comparison in this phase [4]. A further uncontrolled MRS study found more phosphocreatine (+7%) and ATP (+14%) in the anterior cingulate gyrus [5].

Clinically, citicoline has been tested mainly after stroke and in cognitive disorders. The ICTUS trial with 2298 people was stopped for futility: recovery after 90 days was the same with citicoline and placebo [6]. A Cochrane review found indications of benefit for memory and behavior in older people with chronic brain disorders, but not for attention [1]; a more recent meta-analysis in dementia and mild cognitive impairment found positive effects with poor overall study quality [7].

Targets

TargetTypeActionKey dataEvidence
Phosphatidylcholine synthesis (Kennedy pathway)Signaling pathwayActivatorphosphodiesters +7.3% after 6 weeks (human, uncontrolled) Human, non-randomised[1][3][4]
Phospholipase A2EnzymeInhibitor Animal study[3]
α7 nicotinic acetylcholine receptor (via choline)ReceptorAgonist Laboratory[9]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamine↑ · tyrosine hydroxylase activity and dopamine release increased (animal data according to a review)[3]
  • Noradrenalineno data
  • Serotoninno data
  • Acetylcholine↑ · supplies choline for acetylcholine (animal data according to a review); choline in the blood rises in humans[2][3]
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flowno data
  • Nitric oxideno data
  • Energy metabolism↑ · more phosphocreatine and ATP in the frontal cortex (uncontrolled MRS study)[5]
  • Insulin · glucoseno data
  • Inflammation · oxidative↓ · less lipid peroxidation, more glutathione after ischemia (rodents)[3]
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Human studies

  • ICTUS: acute ischemic stroke

    RCT, placebo-controlled, multicenter · Patients: moderate to severe ischemic stroke · n = 2298 · 6 weeks of treatment, endpoint after 90 days

    Measured: global recovery (NIHSS, Rankin, Barthel)

    Result: No difference (OR 1.03; 95% CI 0.86–1.25); stopped for futility. Funded by the manufacturer.[6]

    Human, randomised

  • Cochrane review of chronic brain disorders in old age

    systematic review of 14 RCTs · Patients: older people with cognitive disorders · 20 days to 12 months

    Measured: Attention, memory, behavior, overall impression

    Result: Indications of benefit for memory, behavior, and overall impression; no benefit for attention; well tolerated.[1]

    Human, randomised

  • Memory in older healthy people with age-related memory complaints

    RCT, double-blind, placebo-controlled · healthy (50–85 years, age-associated memory impairment) · n = 100 · 12 weeks

    Measured: computer-based memory tests

    Result: Episodic memory and composite memory score better (secondary endpoints); co-authored by the manufacturer.[10]

    Human, randomised

  • Attention and motor function in adolescents

    RCT, placebo-controlled · healthy (male adolescents) · n = 75 · 28 days

    Measured: Ruff 2&7, finger tapping, CPT-II

    Result: Attention (p = 0.02) and psychomotor speed (p = 0.03) better; co-authors from the manufacturer.[11]

    Human, randomised

  • Sensory gating in healthy people

    RCT, double-blind, placebo-controlled, single dose · healthy · n = 24 · Single dose

    Measured: P50 suppression, Groton maze learning task

    Result: Better gating only in people with a low baseline value; maze task only a trend.[9]

    Human, randomised

  • Phospholipids in the brain of older healthy people

    6 weeks open-label, then randomized · healthy (older people) · 12 weeks

    Measured: 31P-MRS: phosphodiesters

    Result: Phosphodiesters +7.3% after the open-label phase; no further rise afterward.[4]

    Human, non-randomised

Risks and warnings

  • Adverse effects

    In the ICTUS trial with 2298 people, no differences in safety endpoints and adverse events compared with placebo [6]; well tolerated in the Cochrane review [1].

    Human, randomised

  • Manufacturer involvement

    ICTUS was funded by the manufacturer [6]; the studies in healthy people used a branded product or had manufacturer employees as co-authors [5][10][11].

    No data

Fact check: common claims

  • partly supported

    “Citicoline improves memory in healthy people”

    One RCT in older healthy people with memory complaints showed advantages in secondary endpoints [10]; another study found no effect, and EFSA saw no cause-and-effect relationship [8].

  • partly supported

    “Citicoline increases focus and attention”

    Better attention in an RCT in adolescents with manufacturer involvement [11]; the Cochrane review found no effect on attention in older people [1].

  • refuted

    “Citicoline improves recovery after a stroke”

    For moderate to severe ischemic strokes, the large ICTUS trial found no difference from placebo [6].

  • not supported

    “Citicoline raises dopamine”

    Only animal data, summarized in a review [3]; not measured in humans.

Pharmacokinetics

Absorption
Oral; choline and uridine rise in the blood, cytidine is hardly detectable [2].
Half-life
Not verified; choline and uridine remained elevated for 5–10 hours after a single dose [2].
Metabolism
Cleavage into choline and cytidine; in humans, cytidine is largely converted to uridine [2].
Entry into the brain
Indirect: changes in phospholipid and energy metabolites in the brain in MRS studies [4][5].

Legal status

Germany
Not verified.
EU
Frequently prescribed in several European countries for cognitive disorders [1]; in 2024, EFSA saw no cause-and-effect relationship for a memory claim on foods [8].
USA
Not verified.
Other countries
According to the ICTUS trial, authorized in some countries for the treatment of acute ischemic stroke [6].

Related compounds

Uridinactive metabolite (German only)Alpha-GPCsame classCentrophenoxinsame class (German only)

Open questions

  • Do independent, sufficiently large RCTs confirm the memory effect in older healthy people as a primary endpoint?
  • How much of the effect is due to uridine, and how much to choline?
  • Do the MRS changes in the brain have a measurable functional benefit?

References

  1. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. doi:10.1002/14651858.CD000269.pub3 · PubMed
  2. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989–92. doi:10.1016/s0006-2952(00)00436-6 · PubMed
  3. Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. 2002;80(1):12–23. doi:10.1046/j.0022-3042.2001.00697.x · PubMed
  4. Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002;161(3):248–54. doi:10.1007/s00213-002-1045-y · PubMed
  5. Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066–75. doi:10.1002/nbm.1281 · PubMed
  6. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349–57. doi:10.1016/S0140-6736(12)60813-7 · PubMed
  7. Bonvicini M, Travaglini S, Lelli D, Antonelli Incalzi R, Pedone C. Is citicoline effective in preventing and slowing down dementia? A systematic review and a meta-analysis. Nutrients. 2023;15(2):386. doi:10.3390/nu15020386 · PubMed
  8. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, et al. ‘Citicoline’ and support of the memory function: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J. 2024;22(7):e8861. doi:10.2903/j.efsa.2024.8861 · PubMed
  9. Knott V, Smith D, de la Salle S, Impey D, Choueiry J, Beaudry E, et al. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. J Psychopharmacol. 2014;28(12):1095–108. doi:10.1177/0269881114553254 · PubMed
  10. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021;151(8):2153–60. doi:10.1093/jn/nxab119 · PubMed
  11. McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121–34. doi:10.1177/1087054715593633 · PubMed
How this profile was checked

Last reviewed: 2026-10-23. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-23); translation checked on 2026-10-26.

Checked

  • All DOIs resolved via Crossref, PMIDs match the DOIs.
  • Checked against the abstract: 14 RCTs, benefit for memory and behavior, not for attention, frequent prescription in Europe [1]; twelve people, choline and uridine raised, cytidine not detectable [2]; PLA2, glutathione, tyrosine hydroxylase, and dopamine [3]; phosphodiesters +7.3%, open-label first phase [4]; phosphocreatine +7%, ATP +14%, 16 people, branded product Cognizin [5]; n = 2298, OR 1.03, stopped, funding by the manufacturer, authorization in some countries [6]; seven studies, poor quality [7]; n = 100, secondary endpoints, manufacturer employees among those involved [10]; n = 75, p = 0.02/0.03, manufacturer employees among those involved [11]; n = 24, gating only at a low baseline value [9]; EFSA: no cause-and-effect relationship, one positive and one negative study in healthy people [8].
  • ClinicalTrials.gov: 74 entries for citicoline (October 23, 2026).
  • Precision flags (m004; rules of the guideline of October 26, 2026; participant numbers, direction, and funding checked on October 26, 2026 via PubMed efetch against the abstract, conflict-of-interest statement, and affiliations): “Better mental performance in healthy people”: “herstellerfinanziert” – [10] affiliations Kyowa Hakko Bio and Kyowa Hakko USA (Cognizin), [11] co-authors at Kyowa Hakko Bio ([8] EFSA opinion, not a study).
  • October 26, 2026, cross-check of the precision flags (m004): evidence for the flags set also added to the begruendung (“Evidence for …”, guideline “Präzisions-Flags”); figures and statements checked again via PubMed efetch (abstract, conflict-of-interest and funding statements, affiliations): [10] affiliations Kyowa Hakko Bio Co., Ltd. and Kyowa Hakko USA Inc., [11] affiliations KYOWA HAKKO BIO CO., LTD and KYOWA HAKKO U.S.A., INC.

Not verified

  • Whether the primary endpoint of [10] was missed; the abstract reports only secondary endpoints as significant.
  • Legal status in Germany (medicinal product, dietary supplement, novel food) and the US not checked in registers.
  • Sample size of [4] not given in the abstract.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.